[Innovative surgical treatment approaches for endothelial dysfunction : Descemet stripping only (DSO) and endothelial cell injection].

Die Ophthalmologie Pub Date : 2024-10-01 Epub Date: 2024-10-11 DOI:10.1007/s00347-024-02119-0
V Tahmaz, M Mestanoğlu, A Howaldt, B O Bachmann, M Matthaei, C Cursiefen
{"title":"[Innovative surgical treatment approaches for endothelial dysfunction : Descemet stripping only (DSO) and endothelial cell injection].","authors":"V Tahmaz, M Mestanoğlu, A Howaldt, B O Bachmann, M Matthaei, C Cursiefen","doi":"10.1007/s00347-024-02119-0","DOIUrl":null,"url":null,"abstract":"<p><p>Currently, due to a rising number of patients Germany and many other countries experience a large deficit of donor eyes for posterior lamellar keratoplasty procedures in the treatment of corneal endothelial diseases. To address this unmet need there is an ongoing investigation of treatment modalities which do not rely on donor tissue or enable clinicians to treat more patient eyes per donor eye. The authors introduce a promising approach for both treatment principles. First, the technique of Descemet stripping only (DSO) is detailed, in which a central part of the Descemet's membrane including the endothelium is surgically removed without replacement with donor tissue. This then allows endothelial cells from the periphery of the cornea to migrate into the central area and can reduce corneal opacification and swelling. As a representative technique of the second group, the authors introduce endothelial cell injection, in which human corneal endothelial cells are cultivated in vitro and then, after removal of the diseased endothelium, injected into the anterior chamber of the recipient's eye to form a new and healthy endothelium. This is supported by injection of Rho kinase inhibitors and a face-down positioning of the patient after surgery. It is postulated that endothelial cell injection could possibly enable clinicians to treat up to 300 patient eyes with the tissue generated from 1 donor eye. Whether and how these novel approaches will become established in Europe remains to be seen.</p>","PeriodicalId":72808,"journal":{"name":"Die Ophthalmologie","volume":" ","pages":"796-802"},"PeriodicalIF":0.0000,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Die Ophthalmologie","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1007/s00347-024-02119-0","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/10/11 0:00:00","PubModel":"Epub","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Currently, due to a rising number of patients Germany and many other countries experience a large deficit of donor eyes for posterior lamellar keratoplasty procedures in the treatment of corneal endothelial diseases. To address this unmet need there is an ongoing investigation of treatment modalities which do not rely on donor tissue or enable clinicians to treat more patient eyes per donor eye. The authors introduce a promising approach for both treatment principles. First, the technique of Descemet stripping only (DSO) is detailed, in which a central part of the Descemet's membrane including the endothelium is surgically removed without replacement with donor tissue. This then allows endothelial cells from the periphery of the cornea to migrate into the central area and can reduce corneal opacification and swelling. As a representative technique of the second group, the authors introduce endothelial cell injection, in which human corneal endothelial cells are cultivated in vitro and then, after removal of the diseased endothelium, injected into the anterior chamber of the recipient's eye to form a new and healthy endothelium. This is supported by injection of Rho kinase inhibitors and a face-down positioning of the patient after surgery. It is postulated that endothelial cell injection could possibly enable clinicians to treat up to 300 patient eyes with the tissue generated from 1 donor eye. Whether and how these novel approaches will become established in Europe remains to be seen.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
[内皮功能障碍的创新手术治疗方法 :单纯去骨瓣剥离术(DSO)和内皮细胞注射术]。
目前,由于患者人数不断增加,德国和许多其他国家在治疗角膜内皮疾病的后板层角膜移植手术中都面临着供体严重不足的问题。为了满足这一未获满足的需求,人们正在研究不依赖供体组织的治疗模式,或使临床医生能用每只供体眼治疗更多患者的眼睛。作者针对这两种治疗原则介绍了一种很有前景的方法。首先,作者详细介绍了单纯德斯梅特剥离(DSO)技术,即通过手术切除包括内皮在内的德斯梅特膜中央部分,而不使用供体组织替代。这样,角膜周边的内皮细胞就会迁移到中央区域,从而减轻角膜不透明和肿胀。作为第二类技术的代表,作者介绍了内皮细胞注射技术,即在体外培养人类角膜内皮细胞,然后在去除病变内皮后,将其注射到受者眼睛的前房中,形成新的健康内皮。这需要注射 Rho 激酶抑制剂和手术后患者脸朝下的姿势。据推测,内皮细胞注射有可能使临床医生利用 1 只供体眼产生的组织治疗多达 300 名患者的眼睛。这些新方法能否以及如何在欧洲推广还有待观察。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
自引率
0.00%
发文量
0
期刊最新文献
[Recurrent strabismus with nystagmus : Serious problem-Easy to overlook]. [A new validated ophthalmic patient questionnaire for cataract and lens surgery : CLOQ: cataract and lens ophthalmic questionnaire]. [Gender distribution of scientific contributions at German ophthalmological conferences-a baseline study]. [High blood pressure rarely occurs alone]. [Academics in ophthalmology : An analysis of the gender distribution at German university hospitals and the Clinician Scientist Program].
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1